Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 3/2018

01-06-2018 | Original Article

A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma

Authors: Shuji Hiramoto, Ken Kato, Hirokazu Shoji, Natsuko Okita, Atsuo Takashima, Yoshitaka Honma, Satoru Iwasa, Tetsuya Hamaguchi, Yasuhide Yamada, Yasuhiro Shimada, Narikazu Boku

Published in: International Journal of Clinical Oncology | Issue 3/2018

Login to get access

Abstract

Background

Patients with metastatic or recurrent esophageal squamous cell carcinoma (ESCC) have a poor prognosis. For decades, the most widely used first-line chemotherapy regimen for these patients has been the combination of 5-fluorouracil + cisplatin (CF). However, prognostic factors of CF as first-line chemotherapy for ESCC have not been clarified.

Methods

A total of 187 patients with metastatic or recurrent esophageal ESCC treated with CF at the National Cancer Center Hospital between January 2001 and December 2012 were enrolled in the study. The CF regimen comprised cisplatin (80 mg/m2) administered on day 1 and 5-fluorouracil (800 mg/m2) administered continuously on days 1–5, every 4 weeks. Multivariate Cox regression analysis was used to determine the potential prognostic factors.

Results

The median age of the patients was 62 (range 34–84) years. Metastasis and recurrence occurred in 116 and 71 of these patients, respectively. The overall response rate was 37.2%, with median progression-free and overall survival times of 4.8 and 10.4 months, respectively. In the multivariate analysis, higher serum C-reactive protein level and lower serum albumin level at the time of CF treatment initiation and number of metastatic sites were identified as independent prognostic factors for survival.

Conclusions

The results of this study corroborate previous findings on the efficacy of CF and will aid physicians in clinical decision-making and individual patient risk stratification, as well as in the further development of chemotherapy regimens.
Literature
1.
2.
3.
Coonley CJ, Bains M, Hilaris B et al (1984) Cisplatin and bleomycin in the treatment of esophageal carcinoma. A final report. Cancer 54(11):2351–2355CrossRefPubMed
4.
Marcullo E, Alba E, de Segura GG (1988) Cisplatin and intravenous continuos infusion of bleomycin in advanced and metastatic esophageal cancer. Eur J Cancer Clin Oncol 24(4):633–635CrossRef
5.
Iizuka T, Kakegawa T, Ida H et al (1991) Phase II evaluation of combined cisplatin and vindecine in advanced squamous cell carcinoma of the esophagus. Jpn J Clin Oncol. 21(3):176–179PubMed
6.
Dinwoodie WR, Bartolucci AA, Lyman GH et al (1986) Phase II evaluation of cisplatin, bleomycine in advanced squamous cell carcinoma of the esophagus. Cancer Treat Rep 70(2):267–270PubMed
7.
Kok TC, Van der Gaast A, Dees J et al (1996) Cisplatin and etoposide in oesophageal cancer; a phase II study. Rotterdam Oesophageal Tumor Study Group. Br J Cancer 74(6):980–984CrossRefPubMedPubMedCentral
8.
Bleiberg H, Conroy T, Paillot B et al (1997) Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33(8):1216–1220CrossRefPubMed
9.
Iizuka T, Kakegawa T, Ide H et al (1992) Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: Japan Esophageal Oncology Group Trial. Jpn J Clin Oncol 22:172–176PubMed
10.
Hayashi K, Ando N, Watanabe H et al (2001) Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group Trial (JCOG9407). Jpn J Clin Oncol 31(9):419–423CrossRefPubMed
11.
Ando N, Kato H, Igaki H et al (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19(1):68–74CrossRefPubMed
12.
Muro K, Hmaguchi T, Ohtsu A et al (2004) A phase II study of single-agent in phase with metastatic esophageal cancer. Ann Oncol 15(6):955–959CrossRefPubMed
13.
Kato K, Tahara M, Hironaka S et al (2011) A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 67(6):1265–1272CrossRefPubMed
14.
Shirakawa T, Kato K, Nagashima K et al (2014) A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine-and platinum-based chemotherapy. Cancer Chemother Pharmacol 74(6):1207–1215CrossRefPubMed
15.
Tamura S, Imano M, Takiuchi H et al (2012) Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer Res 32:1403–1408PubMed
16.
Osaka Y, Shinohara M, Hoshino S et al (2011) Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. Anticancer Res 31:633–638PubMed
17.
Hironaka S, Tsubosa Y, Mizusawa J et al (2014) Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Cancer Sci 105(9):1189–1195CrossRefPubMedPubMedCentral
18.
Kato K, Muro K, Ando A et al (2014) A phase II of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus (JCOG9905-DI). Esophagus 11:183–188CrossRef
19.
Forrest LM, McMillan DC, McArdle CS et al (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89:1028–1030CrossRefPubMedPubMedCentral
20.
Nozoe T, Ninomiya M, Maeda T et al (2010) Prognostic nutritional index: a tool to predict the biological aggressivenesss of gastric carcinoma. Surg Today 40:440–443CrossRefPubMed
21.
Maeda K, Shibutani M, Otani H et al (2014) Low nutritional prognostic index correlates with poor survival in patients with stage IV colorectal cancer following palliative resection of the primary tumor. World J Surg 38:1217–1222CrossRefPubMed
22.
Kanda M, Fujii T, Kodera Y et al (2011) Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg 98:268–274CrossRefPubMed
23.
Masaichi O, Naoshi K, Go M et al (2015) Glasgow prognostic score as a prognostic clinical marker in T4 esophageal squamous cell carcinoma. Anticancer Res 35:4897–4902
24.
Okuno T, Wakabayashi M, Kato K et al (2017) Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303). Int J Clin Oncol 22(6):1042–1049
Metadata
Title
A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma
Authors
Shuji Hiramoto
Ken Kato
Hirokazu Shoji
Natsuko Okita
Atsuo Takashima
Yoshitaka Honma
Satoru Iwasa
Tetsuya Hamaguchi
Yasuhide Yamada
Yasuhiro Shimada
Narikazu Boku
Publication date
01-06-2018
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 3/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-018-1239-x

Other articles of this Issue 3/2018

International Journal of Clinical Oncology 3/2018 Go to the issue

Special Article

Meta-analysis of randomized clinical trials in the era of individual patient data sharing

Original Article

The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations

Invited Review Article

A systematic review of publications on charged particle therapy for hepatocellular carcinoma

Original Article

Comparison of the diagnostic efficacy and perioperative outcomes of limited versus extended pelvic lymphadenectomy during robot-assisted radical prostatectomy: a multi-institutional retrospective study in Japan

Original Article

No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer

Original Article

Characteristics of MUTYH variants in Japanese colorectal polyposis patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits